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b1- and b2-adrenergic receptors (bARs) are highly homo-
logous, yet they play clearly distinct roles in cardiac
physiology and pathology. Myocyte contraction, for
instance, is readily stimulated by b1AR but not b2AR
signaling, and chronic stimulation of the two receptors
has opposing effects on myocyte apoptosis and cell survival.
Differences in the assembly of macromolecular signaling
complexes may explain the distinct biological outcomes.
Here, we demonstrate that b1AR forms a signaling complex
with a cAMP-speciﬁc phosphodiesterase (PDE) in a manner
inherently different from a b2AR/b-arrestin/PDE complex
reported previously. The b1AR binds a PDE variant,
PDE4D8, in a direct manner, and occupancy of the
receptor by an agonist causes dissociation of this complex.
Conversely, agonist binding to the b2AR is a prerequisite for
the recruitment of a complex consisting of b-arrestin and the
PDE4D variant, PDE4D5, to the receptor. We propose that the
distinct modes of interaction with PDEs result in divergent
cAMP signals in the vicinity of the two receptors, thus,
providing an additional layer of complexity to enforce the
speciﬁcity of b1-a n db2-adrenoceptor signaling.
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Introduction
To meet the increased metabolic demands of stress or
exercise, the sympathetic nervous system stimulates cardiac
function through activation of the closely related b1- and
b2-adrenergic receptors (b1AR and b2AR). Even though
these highly homologous receptors both activate the G
protein stimulatory for adenylyl cyclase (Gs), signaling through
b1AR and b2AR produces clearly distinguishable biological
effects (Xiang and Kobilka, 2003; Xiao et al,2 0 0 4 ) .T h eb1AR
plays the dominant role in stimulating heart rate and strength
of myocyte contraction, whereas b2AR produces only modest
chronotropic effects. Chronic stimulation of b1AR produces
myocyte hypertrophy and apoptosis, whereas b2AR signaling
promotes cell survival. The assembly of distinct macromole-
cular signaling complexes with transducer, scaffold, and effec-
tor proteins, which determine signaling properties and
subcellular localization of the bARs, is thought to be at the
core of the divergent properties of these receptors (Xiang and
Kobilka, 2003; Xiao et al, 2004). Thus, understanding
the differences of these receptor complexes has important
pharmacological and clinical implications.
One of the emerging mechanisms that safeguard the
speciﬁcity of G-protein-coupled receptor/cAMP signaling is
the control of cAMP transients via degradation by cyclic
nucleotide phosphodiesterases (PDEs) (Conti and Beavo,
2007). Biochemical, electrophysiological, and in vivo imaging
studies are consolidating the idea that occupancy of different
receptors generates a nonuniform pattern of activation of
cAMP effector proteins such as PKA (cAMP-dependent
protein kinase). PDEs play a critical role for the speciﬁcity
in cAMP-signaling by preventing the free diffusion of cAMP,
thus, effectively creating cyclic nucleotide microdomains
and/or cAMP gradients that can be sensed by the cell
(Zaccolo and Pozzan, 2002; Xiang et al, 2005; Fischmeister
et al, 2006).
PDEs comprise a large group of over 20 genes that
are divided into 11 PDE families based on their amino-
acid sequence homology, substrate speciﬁcities, and
pharmacological properties (Conti and Beavo, 2007). Each
of the 11 PDE families encompasses one to four distinct
genes. In addition, most PDE genes encode for multiple
splicing variants through the use of multiple promoters and
alternative splicing.
Previous studies indicated that occupancy of the b2AR
initiates the recruitment of a preformed complex consisting
of b-arrestin and the cyclic AMP-speciﬁc PDE, PDE4D5 (Perry
et al, 2002; Baillie et al, 2003). Conversely, no data are
available on complexes between PDEs and the b1AR even
though it has been shown that PDE4 inhibitors potentiate
cAMP accumulation induced by either b1AR or b2AR (Xiang
et al, 2005). Here, we show that b1AR forms a signaling
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384complex with a PDE4D splicing variant in a manner
inherently different from the b2AR/b-arrestin/PDE complex
reported previously. Thus, this study challenges the assump-
tion that the regulation of receptor signaling by PDEs de-
scribed for the b2AR also applies to b1AR. We propose that
the distinct modes of interaction with PDEs provide an
additional layer of complexity to enforce the speciﬁcity of
b1- and b2-adrenoceptor signaling.
Results
Detection of a b1AR/PDE4D signaling complex in mouse
neonatal cardiac myocytes
To probe for a possible signaling complex including the b1AR
and a PDE, mouse neonatal cardiomyocytes were infected
with an adenovirus encoding a Flag-tagged b1AR, and the
receptor was subsequently immunoprecipitated using an
antibody against the tag. A signiﬁcant amount of endogenous
PDE activity was recovered in the b1AR immunoprecipitation
(IP) pellet (Figure 1A). The PDE activity associated with the
b1AR was inhibited by the PDE4-selective inhibitor, Rolipram,
identifying this activity as PDE4. Three PDE4 subtypes,
PDE4A, PDE4B, and PDE4D, are expressed in neonatal car-
diomyocytes at comparable levels (Figure 2B). The fourth
gene, PDE4C, is not expressed in the heart and was not
investigated. To assess which of the PDE4 subtypes contri-
bute to the activity recovered in the b1AR IP, cardiomyocytes
deﬁcient in PDE4A, PDE4B, and PDE4D were subjected to
pull-down experiments. Whereas ablation of PDE4A or
PDE4B had no effect, inactivation of the PDE4D gene pre-
vented co-IP of PDE activity with the b1AR (Figure 1B). Thus,
PDE4D is the endogenous PDE recovered in complex with the
receptor. This conclusion is further supported by western blot
analysis of the immunoprecipitated PDE. A band immunor-
eactive with PDE4D-selective antibodies was consistently
detected in the IP pellet (Figure 1C), and its mobility is
consistent with that of a subset of PDE4D splicing variants
that include PDE4D3, PDE4D8, and PDE4D9 (Richter et al,
2005). Together, these data suggest the presence of a signaling
complex containing the b1AR, a PDE4D isoform, and perhaps
other components of the cAMP signaling pathway in cardiac
myocytes.
Distinct PDE4D splice variants co-IP with the b1AR
Through alternate splicing and the use of multiple promoters,
nine different proteins, PDE4D1–9, originate from the PDE4D
gene (Richter et al, 2005; Figure 2D). These proteins are
identical in the catalytic domain and C-terminus but diverge
at the N-terminus. Long forms contain a conserved UCR1/UCR2
(upstream conserved regions 1 and 2) motif, whereas short
forms lack UCR1 and part of UCR2 (Conti et al, 2003; Houslay
and Adams, 2003). Using antibodies raised against the unique
N-terminus of each variant, we determined that PDE4D5,
PDE4D8, and PDE4D9 are the splicing variants most
abundant in cardiomyocytes, with trace amounts of PDE4D3
(Figure 2C). The co-IP of these PDE4D splice variants
expressed exogenously in HEK293 cells identiﬁed PDE4D8
as the variant that most efﬁciently interacts with b1AR. Other
long PDE4D splice variants were also recovered in b1AR IP
pellets with the following rank order: PDE4D84PDE4D94
PDE4D34PDE4D5 (Figure 3A and B). Conversely, the short
PDE4D form, PDE4D2, did not co-IP with the b1AR, indicating
that the UCR domains unique to long PDE4 splice variants
may contribute to the formation of the b1AR/PDE4D
complex.
PDE4D binds directly to the b1AR
As previously reported, tethering of PDE4D5 to the b2AR
signaling complex is mediated by b-arrestins (Baillie et al,
2003). However, the co-IP of exogenous PDE4D and b1AR
from extracts of mouse embryonic ﬁbroblasts (MEFs) deﬁ-
cient in b-arrestin 1 and 2 (Kohout et al, 2001) was not
decreased compared with wild-type controls, suggesting
that formation of the b1AR/PDE4D complex is independent
of b-arrestins (Figure 3C). To further characterize the inter-
action, we performed IPs using PDE4D and bARs that were
puriﬁed from a baculovirus expression system to 490%
purity (see Supplementary Figure 1 for the characterization
of the puriﬁed proteins). In this paradigm, PDE4D shows
robust association with b1AR but not with b2AR (Figure 3D
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Figure 1 A b1AR/PDE4D signaling complex in mouse neonatal cardiomyocytes. Shown are IPs of a Flag-tagged b1AR from detergent extracts of
mouse neonatal cardiomyocytes. (A) Total, non-PDE4, and PDE4 activity in the IP pellet. (B) Co-IP of b1AR and PDE activity from
cardiomyocytes deﬁcient in PDE4A, PDE4B, or PDE4D, and wild-type controls. (C) Western blot with the b1AR IP from wild-type myocytes.
The migration of the PDE4D-immunoreactive band in the IP pellet corresponds to that of PDE4D splicing variants PDE4D3, PDE4D8, and
PDE4D9. Data shown represent the means7s.e.m. (A, B) or are representative (C) of at least three experiments performed.
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b1AR/PDE4D complex. More importantly, this approach
clearly indicates that PDE4D binds directly to the b1AR but
has no signiﬁcant, or a much reduced afﬁnity for b2AR.
Binding of b-adrenergic agonists induces dissociation
of the b1AR/PDE4D complex
To determine whether receptor occupancy affects the
b1AR/PDE4D complex, HEK293 cells expressing exo-
genous b1AR and PDE4D8 were incubated with different
ligands. Treatment with the physiological b1AR agonist,
( )-Norepinephrine (NorEpi), caused dissociation of the
b1AR/PDE4D complex (Figure 4A and B), whereas the
stereoisomer, (þ)-norepinephrine, which is a poor b1AR
ligand, had no effect. Dissociation of the b1AR/PDE4D
complex was observed also in cardiac myocytes and
b-arrestin-deﬁcient MEFs (Supplementary Figures 3 and 4)
and occurred whether the overexpressed PDE4D was
catalytically active or inactive (Supplementary Figure 5).
Dissociation of the b1AR/PDE4D complex by NorEpi binding
is rapid (T1/2o1min; Figure 4C and D) and dose-dependent
(Figure 4E and F), reaching maximum at approximately
100 mM NorEpi. Thus, the concentration-dependence of dis-
sociation of the b1AR/PDE4D complex is comparable to that
of receptor occupancy by NorEpi rather than that of receptor-
induced cAMP production, which is in the nanomolar range.
In addition, washout of the agonist results in b1AR/PDE4D
reassociation (data not shown). This dynamic, receptor
occupancy-dependent regulation of b1AR/PDE4D complex
formation may explain why b1AR/PDE4D dissociation is
not complete and some portion of receptor/PDE complexes
(B30%) remain at any given time point. Treatment with the
b-adrenergic agonists, isoproterenol (ISO; 10mM; see
Supplementary Figure 5) or Epinephrine (100mM; data not
shown), also promoted dissociation of the b1AR/PDE4D
complex.
Selective activation of PDE4D splice variants upon
stimulation of b1AR and b2AR
All PDE4 long forms are activated by phosphorylation at a
conserved PKA consensus site in UCR1 (see Figure 2D); this
mechanism provides a ubiquitous negative-feedback loop
critical for cAMP signaling (Conti et al, 2003). Accordingly,
stimulation of cultured neonatal cardiac myocytes with
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of PDE4D (Supplementary Figure 2A–C). If complexes
composed of bARs and PDEs are present in these cells,
phosphorylation should be biased toward the PDEs present
in the vicinity of the occupied receptors. This is indeed the
case when b1AR- and b2AR-stimulated phosphorylation of
PDE4D isoforms was monitored. In cardiomyocytes lacking
b2AR, PDE4D8 was the PDE4D isoform predominantly acti-
vated after stimulation of b1AR with ISO, with a limited
activation of PDE4D9, and no signiﬁcant effect on PDE4D5
(Figure 5A). Conversely, in myocytes lacking b1AR, stimula-
tion of b2AR causes a selective increase in the activity of
PDE4D5, with a less pronounced increase in PDE4D9, and no
increase in PDE4D8 activity (Figure 5B). Importantly, upon
stimulation with the adenylyl cyclase activator, Forskolin, all
PDE4D isoforms show the same increase in activity in both
cell types (Figure 5C), suggesting that loss of one bAR
subtype or the other has not perturbed overall cAMP signal-
ing. It also demonstrates that the spatial dimension of cAMP
signaling is lost when generalized adenylyl cyclase activation
is induced with Forskolin. The selective activation of PDE4D
splicing variants by b1AR and b2AR signaling conﬁrms the
selectivity observed in the physical association of b1AR with
PDE4D8 (Figure 3A and B) and the preferential sequestration
of PDE4D5 to the b2AR by b-arrestin (Baillie et al, 2003).
Because these experiments are with endogenous proteins,
they strengthen our hypothesis of the presence of PDE4D
variants in complex with b1AR and b2AR in vivo.
PDE4D controls the activity of PKA in the vicinity
of the b1AR
The presence of a PDE4D in the vicinity of the b1AR should
affect the activity of PKA localized with the receptor as well
as the PKA-phosphorylation state of the receptor itself. This
possibility was tested by blocking PDE activity with selective
PDE4 inhibitors in cardiomyocytes (Figure 6A and B), by
using MEFs deﬁcient in PDE4D (Figure 6C and D), or by
overexpressing a catalytically inactive PDE4D in cardiomyo-
cytes, which acts as a dominant-negative construct (Perry
et al, 2002; Baillie et al, 2003) by displacing endogenous
PDE4D from the b1AR complex (Figure 6E and F;
Supplementary Figure 5). In all instances, blockage of PDE4
activity or, more speciﬁcally, ablation or displacement of
PDE4D caused a signiﬁcant increase in the phosphorylation
of the transfected b1AR in the absence of b-adrenergic ago-
nists. It should be noted that inhibition of PDE3 activity or an
overexpression of a dominant-negative PDE3A construct has
no effect on b1AR phosphorylation, conﬁrming the speciﬁcity
of the interactions. These ﬁndings indicate that PDE4D con-
trols the access of cAMP to PKA localized with the b1AR,
effectively creating a domain with low basal cAMP/PKA
activity. PDE4D also limits PKA-phosphorylation of b1AR in
response to low concentrations of b-adrenergic agonists that
do not disrupt a large number of b1AR/PDE4D complexes.
This is likely due to the control of cAMP levels and PKA-
activity in the vicinity of unoccupied, and thus, PDE4D-
associated receptors in response to elevated cellular cAMP
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Figure 3 Interaction of exogenous b1AR and PDE4D. (A, B) Co-IP of exogenous b1AR and Myc-tagged PDE4D splice variants expressed in
HEK293 cells. The efﬁciency with which b1AR pulls down the different PDE4D splice variants is quantiﬁed in (B). (C) Shown is the co-IP of
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plex with the b1AR in the intact cell.
PDE4D ablation promotes b1AR desensitization in vivo
To assess the role of PDE4D in b1AR function in a more
physiological context, changes in the heart rate of mice in
response to b-adrenergic stimulation were measured, as it is
established that in vivo contraction rate is primarily con-
trolled by b1AR (Rohrer et al, 1996, 1999; Devic et al, 2001).
Wild-type and PDE4DKO mice, matched by age, sex, and
genetic background, were sedated using isoﬂurane. While
their heart rate was continuously measured using a mouse
pulse oximeter sensor, the mice were then injected with a
submaximal concentration of ISO. An additional group of
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enhance the heterologous desensitization of b1AR before the
ISO injection. Wild-type and PDE4DKO mice showed no
signiﬁcant differences in basal heart rate (WT¼410752
and 4DKO¼386746beats/min, means7s.e.m.), the maxi-
mal heart rate after ISO injection (WT¼544734 and
4DKO¼515732beats/min), the maximal heart rate after
GLP1 injection (WT¼487714 and 4DKO¼448719beats/
min), or the maximal heart rate after sequential injection of
GLP1 and ISO (WT¼539724 and 4DKO¼581717beats/
min). The rate of return to basal heart rate after the initial
response to ISO was slightly faster in PDE4DKO mice com-
pared with wild-type controls (Figure 7A); however, this
effect was greatly magniﬁed by pretreatment of mice with
GLP1 (Figure 7B; Po0.0001). The faster decrease in heart rate
is in agreement with our stated hypothesis that elevated
levels of cAMP/PKA activity in the vicinity of the b1AR,
due to absence of PDE4D in this compartment, causes an
increased phosphorylation and heterologous desensitization
of b1AR (see Figure 6).
Discussion
With the above ﬁndings, we have identiﬁed a novel signaling
complex that distinguishes b1AR from b2AR. Although both
receptors are in complexes with PDEs, their interactions differ
in terms of the PDE4D splice variant recruited to the receptor,
the mode of interaction with the PDE4D variant, and the
effect of receptor agonists on the complex (see the illustration
in Figure 8). b1AR preferentially associates with PDE4D8 in
cardiomyocytes as shown by co-IP of endogenous PDE with
the b1AR (Figure 1C), as well as the selective activation of
PDE4D8 in intact cells (Figure 5A). This preference of b1AR
for PDE4D8 was conﬁrmed by co-IP experiments with exo-
genous proteins (Figure 3A and B). Conversely, PDE4D5 is
the variant tethered to the b2AR/b-arrestin complex (Baillie
et al, 2003) concurring with the preferential activation of
PDE4D5 upon b2AR signaling (Figure 5B). In pull-down
experiments using puriﬁed proteins (Figure 3D and E),
b1AR efﬁciently interacts with PDE4D, whereas b2AR has
negligible afﬁnity for PDE4D, underscoring the direct mode of
PDE4D–b1AR interaction versus the indirect, b-arrestin-de-
pendent mode of PDE4D–b2AR interaction. The most impor-
tant difference regarding the function of bARs is the effect of
receptor occupancy on the PDE4D complexes. The b1AR/
PDE4D complex is present in the absence of agonist and
dissociates after receptor occupancy, whereas agonist binding
to the b2AR is a prerequisite for the recruitment of the
b-arrestin/PDE4D complex to the receptor. Thus, under
basal conditions, PDE4D is poised to control local cAMP
concentration and PKA activity in the vicinity of the b1AR
(see Figure 6), whereas it affects b2AR signaling only after
ligand binding and b-arrestin recruitment. These differences
likely impact the time course of cAMP accumulation in the
vicinity of the receptors. We propose that these divergent
interactions with PDE4D variants specify the property of the
signals emanating from the two receptors.
Tethering of PDE4D to the b1AR provides a means to target
cAMP hydrolytic activity in the vicinity of the unoccupied
receptor, thus, preventing a local increase in cAMP under
basal conditions. This, in turn, protects the b1AR from PKA-
mediated phosphorylation and desensitization (Rapacciuolo
et al, 2003; Gardner et al, 2006) and may control PKA-
mediated phosphorylation of other localized substrates.
Indeed, when PDE4 activity is inhibited in cardiomyocytes
(Figure 6A and B), is absent, as in the PDE4D-deﬁcient MEFs
(Figure 6C and D), or is displaced, as in PDE4D-DN infected
cardiomyocytes (Figure 6E and F), a substantial increase in
basal b1AR receptor phosphorylation is observed. In addition
to controlling basal cAMP accumulation, targeting of PDE4D
to the b1AR may prevent heterologous desensitization of
unoccupied receptors. Consistent with this idea, we report
here that PDE4D deﬁciency accelerates the desensitization of
b-adrenergic signals measured as changes in mouse heart rate
in response to ISO injection (Figure 7). At the same time and
given the observation that occupancy of the b1AR causes
dissociation of the complex, it is likely that the ligand-
induced dissociation of PDE4D from the b1AR cooperates to
produce a localized increase in cAMP in the proximity of the
occupied receptor. This event should decrease local cAMP
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Figure 5 Selective activation of PDE4D splicing variants after stimulation of b1AR and b2AR. (A, B) Neonatal cardiac myocytes derived from
mice deﬁcient in b2AR were stimulated for 3min with 100nM ISO (A) and cells deﬁcient in b1AR were treated for 3min with 10mM ISO (B). At
the end of incubation, cells were lysed, PDE4D5, 8, and 9 were immunoprecipitated with variant-speciﬁc antibodies, and the PDE activity
recovered in the IP pellet was measured. Data shown are expressed as the means7s.e.m. of at least three experiments performed.
(C) Activation of PDE4D splice variants after treatment of neonatal cardiac myocytes with 100mM Forskolin for 20min. Shown is the average
of ﬁve experiments; three experiments performed using myocytes deﬁcient in b2AR and two experiments using cells deﬁcient in b1AR.
NS (PX0.05); *(Po0.05); **(Po0.005); ***(Po0.0005).
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locally. Consistent with this view, localized cAMP transients
in the dyad space are elevated in the PDE4DKO mouse,
whereas global cAMP signaling is not perturbed (Lehnart
et al, 2005). The fate and function of the released PDE4D are
to be determined and may provide a means to regulate a
distinct pool of cAMP away from the membrane.
Using changes in the heart rate of mice in response to
b-adrenergic stimulation as a read-out, we show here that
PDE4D deﬁciency promotes an accelerated desensitization of
b1AR signaling. Although additional steps in excitation con-
traction coupling may also be affected by the absence of
PDE4D, this observation is consistent with the idea that a
major function of PDE4D in the b1AR signaling complex is to
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Figure 6 PDE4D in the b1AR complex controls local PKA activity. (A, B) Neonatal cardiac myocytes expressing a Flag-tagged b1AR were
treated for 3min with 100nM Norepinephrine before cell lysis and IP with M1 (a-Flag) resin. The effect of a 5min pre-treatment with 10mMo f
the PDE4-speciﬁc inhibitor, Rolipram, or the PDE3-selective inhibitor, Cilostamide, on PKA-phosphorylation of the b1AR is detected in IBs using
a PKA-site-speciﬁc antibody. (C, D) MEFs derived from mice deﬁcient in PDE4D or wild-type controls were infected with adenovirus to express
a Flag-tagged b1AR construct. At 40h post-infection, cells were treated for 3min with 100nM Norepinephrine (NorEpi) before cell lysis and IP
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sitization. The direct interaction of PDE4D with the receptor,
however, opens additional possibilities for a function of
PDE4D in the b1AR complex. These include a direct effect
of PDE4D on the conformation of the receptor and a role of
PDE4D in the assembly of macromolecular signaling com-
plexes around the b1AR. The latter may include the competi-
tion of PDE4D with other proteins for binding to the receptor
or, in an opposite fashion, PDE4D may act as a scaffold by
tethering additional proteins to the receptor complex such as
the exchange protein activated by cAMP or PKA-anchoring
proteins (Dodge-Kafka et al, 2005). These possibilities will be
addressed in future studies.
Collectively, our ﬁndings demonstrate that stimulation of
b1AR and b2AR has opposing effects on PDE4D recruitment in
the membrane subdomain, with b1AR occupancy causing a
local decrease, whereas b2AR promotes a local increase in
PDE4. A critical role of PDE4s in the submembrane micro-
domain has been described using a modiﬁed CNG channel
as a sensor for cAMP accumulation (Rich et al, 2001). The
dynamic localization of different PDE4D splicing variants that
we report, as well as their phosphorylation state, likely
play a major role in controlling cAMP accumulation in
this submembrane space. This view is consistent with
the alterations in local cAMP accumulation observed in
PDE4D-deﬁcient cardiomyocytes (Lehnart et al, 2005). More
importantly, the PDE4DKO mouse develops a late onset
dilated cardiomyopathy and a propensity to arrhythmias
during exercise (Lehnart et al, 2005). PDE4D-deﬁciency in the
cardiac ryanodine receptor/calcium release channel (RyR2)
complex has been associated with this phenotype. Lack of
PDE4D causes PKA hyperphosphorylation of RyR2 and calsta-
bin depletion from the channel, resulting in a ‘leaky’ RyR2
channel phenotype that, in turn, may contribute to cardiac
arrhythmias. However, disruption of other PDE4D complexes
in the PDE4DKO mouse most likely contributes to the develop-
ment of the cardiac phenotype. The lack of PDE4D in the b1AR
complex and the aberrant b1AR responses described in the
present study may well contribute to the onset of hypertrophy
and heart failure. The observed increased receptor phosphor-
ylation that follows PDE4D deﬁciency (Figure 6) promotes
progressive desensitization (Figure 7) and downregulation of
this receptor, a hallmark in heart failure.
Materials and methods
Antibodies
Recombinant Flag-tagged bARs and Myc-tagged PDE4D splice
variants were detected in western blots using antibodies against
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Figure 7 PDE4D ablation promotes desensitization of b1AR signaling in vivo. Anesthetized mice were sequentially injected with GLP1
followed by a submaximal dose of ISO as described in Materials and methods and the heart rate of the animals was continuously recorded
using pulse oximeter sensor (B). Control mice received ISO only (A). The decline in heart rate after ISO injection in PDE4DKO and wild-type
control mice is reported. Data are expressed as percent of the initial, maximal heart rate in response to ISO injection. Number of mice used for
each measurement is reported among brackets.
Figure 8 Schematic representation of the distinct modes of PDE4
interaction with bAR subtypes. Although both b1AR and b2AR form
signaling complexes with PDE4D splice variants, the complexes
formed by the two receptors are clearly distinguished by the
different PDE4D variants recruited to the receptors (PDE4D8 to
b1AR versus PDE4D5 to b2AR), the mode of interaction with PDE4D
(direct for b1AR versus b-arrestin mediated for b2AR), and the
effect of receptor agonists (induces dissociation or formation of
the complex). In the case of b1AR, a preformed complex with
PDE4D8 that is likely responsible for controlling local cAMP con-
centration and PKA activity in the vicinity of the receptor under
basal conditions is dissociated upon ligand binding. Conversely,
b2AR is not associated with PDE4D under basal conditions but a
preformed complex consisting of b-arrestin and the PDE4D splice
variant, PDE4D5, is recruited to the b2AR after receptor occupancy.
It remains to be determined to what extent PDE4D9, which is
activated after both b1AR and b2AR stimulation (Figure 5) and
which also showed interaction with b1AR in co-IPs of exogenous
proteins (Figure 3A and B), can substitute for interaction with the
bARs in vivo.
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Aldrich; mouse monoclonal a-Myc AB, Roche Applied Sciences).
Endogenous (Figures 1C and 2C) and untagged PDE4D isoforms
(Figure 3D; Supplementary Figures 1 and 2D) were detected using
a mouse monoclonal PAN-PDE4D reactive antibody raised against
the PDE4D C-terminus that is common to all splice variants
(Icos4D). PAN-selective antibodies against PDE4A (AC55), PDE4B
(K118), and PDE4D (M3S1), as well as splice variant-selective
antibodies against PDE4D3, 4, 5, 8, and 9 (Richter et al, 2005), were
used in IPs to determine the expression of the respective PDE4
subtype and splice variant in cardiac myocytes (Figure 2), as well as
their PKA-dependent activation after b-adrenergic stimulation
(Figure 5; Supplementary Figure 2). A PKA-site-speciﬁc antibody
from Cell Signaling (Danvers, MA) was used to measure PKA
phosphorylation of the b1AR (Figure 6). Antibodies against
b-arrestins and PDE3A were kindly provided by Dr R Lefkowitz
and Dr C Yan, respectively.
Design of expression vectors
Cloning of the open reading frames of the nine rat PDE4D splice
variants, PDE4D1–9, has been described previously (Richter et al,
2005). In the present study, these constructs were subcloned into
the pAd/CMV/V5-DEST vector to generate adenoviruses encoding
for C-terminally Myc-tagged PDE4D variants using the ViraPower
Adenoviral Expression System (Invitrogen, Carlsbad, CA). Con-
structs encoding catalytically inactive PDE4D variants were
generated by mutation of a critical histidine residue in the catalytic
site of PDE4D to alanine (His326 in PDE4D3). Adenoviruses
encoding Flag-tagged b1AR and b2AR were generated using the
pAdenovator system (Q-Biogene, Irvine, CA) according to the
manufacturer’s instructions.
Cell culture and adenovirus infection
Ventricular cardiac myocytes were isolated from the excised hearts
of 1–2 day old neonatal mice as described previously (Devic et al,
2001). They were cultured in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) supplemented with 10% Nu Serum IV (BD Falcon), 5%
fetal bovine serum (FBS), 1mM glutamine, 20mg/ml gentamycin,
and 1  ITS media supplement (Sigma) on plates precoated with
10 mg/ml laminin. Experiments were carried out on day 4 of culture.
The use of animals for the experiments followed Stanford
University guidelines and all experiments involving animals were
approved by the Stanford University Administrative Panel on
Laboratory Animal Care. HEK293 and MEF cells were cultured in
DMEM supplemented with 10% FBS, 1mM glutamine, 30mg/ml
penicillin, and 100mg/ml streptomycin. All cells were cultured at
371C and under a 5% CO2 atmosphere. For expression of exogenous
bARs and/or PDE4D constructs, cells were infected with adeno-
viruses 40h before experimentation at an MOI of 2–6 (HEK293),
20–40 (cardiac myocytes), and 100 (MEFs), respectively. As ‘mock’
controls, cells were infected with comparable titers of an
adenovirus encoding green ﬂuorescent protein (GFP).
Immunoprecipitation of Flag-tagged receptors from cell
lysates
After the respective cell treatment, cells were rinsed once with ice-
cold PBS and then lysed in 500ml of 20mM HEPES, 150mM NaCl,
2mM EDTA, 10% glycerol, 1% N-dodecyl-b-D-maltopyranoside
(DDM, Anatrace), 1mM microcystin-LR (Calbiochem), and Com-
plete protease inhibitor cocktail (Roche). Lysates were rotated at
41C for 1h, followed by centrifugation in 14000r.p.m. at 41C for
20min. Soluble extracts were precleared by a 30-min incubation
with 30ml of ProteinG Sepharose. Flag-tagged receptors were then
immunoprecipitated using M1-afﬁnity resin (a-Flag antibody resin;
Sigma Aldrich). After incubation for 4h at 41C, the resin was
washed three times and proteins were eluted in 40ml of elution
buffer (200mg/ml Flag peptide, 20mM HEPES, 50mM NaCl, 0.1%
cholesterol, and 8mM EDTA).
IP of puriﬁed PDE4D and bARs
Rat PDE4D3, expressed in Sf9 insect cells using a recombinant
baculovirus, was puriﬁed to 490% purity using an anti-PDE4D
antibody (M3S1) covalently coupled to ProteinG Sepharose as
described previously (Salanova et al, 1998). Flag-tagged b1AR and
b2AR were also expressed in Sf9 cells and subsequently puriﬁed in a
two-step procedure consisting of an initial afﬁnity chromatography
using M1-resin (immobilized anti-Flag antibody; Sigma Aldrich),
followed by an alprenolol-sepharose afﬁnity column. For bAR/
PDE4D IP, equal amounts of puriﬁed b1AR and b2AR (1mg) were
coupled to M1 resin and then incubated in 500ml of 20mM HEPES
(pH 7.5), 100mM NaCl, 0.1% DDM, 4mM CaCl2, and 0.01%
cholesterol hemisuccinate with 0.5mg of puriﬁed PDE4D under
continuous rotation for 4h at 41C. Afterwards, the resin was washed
three times and proteins were eluted with Flag peptide as described
above.
IP of PDE4 subtypes and splice variants from cell extracts
After 4 days of culture and the respective cell treatment, neonatal
cardiac myocytes were harvested in buffer containing 50mM
Tris–HCl (pH 7.4), 1mM EDTA, 0.2mM EGTA, 150mM NaCl,
5mM b-mercaptoethanol, 10% glycerol, 1mMm i c r o c y s t i n - L R ,
Complete protease inhibitor cocktail (Roche Diagnostics), and 1mM
4-(2-aminoethyl)-benzenesulfonyl ﬂuoride hydrochloride (AEBSF;
Roche Diagnostics). Cell debris was pelleted (14000r.p.m. for
30min), and soluble extracts were immunoprecipitated using 30ml
P r o t e i n GS e p h a r o s ea n dt h er e s p e c t i v eP D E 4s u b t y p e ,o rP D E 4 Ds p l i c e
variant antibodies, as well as IgG as a control. After incubation for 2h
at 41C, the resin was washed three times, and PDE recovered in the
pellet was detected by PDE activity assay or western blotting.
PDE assay
PDE activity was measured as described in detail previously
(Richter and Conti, 2002). PDE4 and PDE3 activity are deﬁned as
the PDE activity inhibited by the PDE4-selective inhibitor, Rolipram
(10mM), or the PDE3-selective inhibitors, Cilostamide or Milrinone
(both 10mM), respectively.
Noninvasive measurement of heart rate in mice
Spontaneously breathing animals were induced with 2% isoﬂurane
and anesthesia was maintained thereafter using 1.25% isoﬂurane. A
mouse pulse oximeter sensor (Mouse Ox, Starr Life Science Corp.,
Allison Park, PA) was then placed on the thigh of the mouse, and
baseline heart-rate data were recorded for 5min. To stimulate
heterologous bAR desensitization, GLP1 (3mgi n2 5 0 ml saline;
Sigma, St Louis, MO) was then given by tail vein injection. When
the heart rate in response to GLP1 injection had peaked (determined
as a return from maximal change in heart rate by maximal 30%), a
submaximal dose of ( )-ISO bitartrate (1.5–3.0mg in 250ml saline;
Sigma, St Louis, MO) was given by intraperitoneal injection. Data
were then acquired until heart rate returned to the animal’s
baseline. The data collected was subsequently analyzed using
Windaq waveform Browser software (DATAQ Instruments). PDE4D-
KO and wild-type control mice used in this study were on the same
genetic background and were matched by sex (six males and one
female each) and age (average age¼7.372.8 months).
Data analysis
Unless otherwise noted, all graphs show the mean7s.e.m. of at
least three experiments performed. Statistical signiﬁcance was
determined using Student’s t-test and is indicated as follows: NS
(PX0.05); *(Po0.05); **(Po0.005); ***(Po0.0005). The Graph-
Pad Prism program (GraphPad Inc., San Diego, CA) was used for all
statistical analyses. For quantiﬁcation of western blot bands, blots
were scanned and the signal intensity of the immunoreactive bands
was quantiﬁed as previously described (Richter and Conti, 2004)
using the ScionImage software program (Frederick, MD).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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